CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Common Shares Follow-On Offering	Common Shares Private Placement	Common Shares	Additional Paid-In Capital Follow-On Offering	Additional Paid-In Capital Private Placement	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Follow-On Offering	Private Placement	Total
Balance at the beginning of the period at Dec. 31, 2019			$ 15			$ 581,467	$ 33	$ (356,092)			$ 225,423
Balance at the beginning of the period (in shares) at Dec. 31, 2019			54,937,628
Changes in equity
Issuance of common shares upon completion of offering, net of placement agent fees	$ 2	$ 1		$ 164,586	$ 55,944				$ 164,588	$ 55,945
Issuance of common shares upon completion of offering, net of placement agent fees (in shares)	8,712,381	3,028,572
Common shares issued or to be issued in connection with the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc. (in shares)			76,103
Issuance of Class A common shares under incentive award plans						6,552					6,552
Issuance of Class A common shares under incentive award plans (in shares)			1,460,338
Share-based compensation expense						20,875					20,875
Unrealized gain (loss) on short-term investments and currency translation adjustments							(67)				(67)
Net income (loss)								(161,381)			(161,381)
Balance at the end of the period at Dec. 31, 2020			$ 18			829,424	(34)	(517,473)			311,935
Balance at the end of the period (in shares) at Dec. 31, 2020			68,215,022
Changes in equity
Issuance of Class A common shares under incentive award plans						5,885					5,885
Issuance of Class A common shares under incentive award plans (in shares)			845,381
Share-based compensation expense						25,173					25,173
Unrealized gain (loss) on short-term investments and currency translation adjustments							(32)				(32)
Net income (loss)								(157,924)			(157,924)
Balance at the end of the period at Dec. 31, 2021			$ 18			860,482	(66)	(675,397)			185,037
Balance at the end of the period (in shares) at Dec. 31, 2021			69,060,403
Changes in equity
Issuance of Class A common shares under incentive award plans			$ 1			2,518					2,519
Issuance of Class A common shares under incentive award plans (in shares)			637,100
Share-based compensation expense						25,120					25,120
Unrealized gain (loss) on short-term investments and currency translation adjustments							110				110
Net income (loss)								183,363			183,363
Balance at the end of the period at Dec. 31, 2022			$ 19			$ 888,120	$ 44	$ (492,034)			$ 396,149
Balance at the end of the period (in shares) at Dec. 31, 2022			69,697,503